Our tech platform
Originating from MIT, we’ve spent years clinically validating our novel platform.
About our platform
Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease, and is personalized based on your brain’s responses.
The platform
Intuitive experience for at-home patient self-administration.
Features:
Personalized treatments
Adjustable fit
Self-administered
How it works
Unlocking potential
01
Self-administered use in the comfort of patients’ homes
02
Personalized sensory stimulation facilitates long-term engagement
03
Support in the palm of your hand
Mechanism of Action
Cognito uses sensory stimulation to evoke gamma oscillations in the brain that have
been shown to improve synaptic connections between neurons, activate microglia, and enhance removal of pathological proteins
from the brain.
This leads to reduced neurodegeneration
and brain atrophy, as well as improved sleep, cognitive and functional abilities.
Our Pipeline
Leveraging our platform across multiple neurodegenerative diseases
Focus
CogTx-001
Alzheimer's Disease
CogTx-002
Mild Cognitive Impairment
CogTx-003
Parkinson's Disease
CogTx-004
Multiple Sclerosis
CogTx-005
Ischemic Stroke
Discovery
Preclinical
Early Clinical
Pivotal Clinical
In market